Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

Pharmacological Actions of a Novel, High-Affinity, and Selective Human Dopamine D3 Receptor Antagonist, SB-277011-A

Charlie Reavill, Stephen G. Taylor, Martyn D. Wood, Tracey Ashmeade, Nigel E. Austin, Kim Y. Avenell, Izzy Boyfield, Clive L. Branch, Jackie Cilia, Martyn C. Coldwell, Michael S. Hadley, A. Jackie Hunter, Phil Jeffrey, Frances Jewitt, Christopher N. Johnson, Declan N. C. Jones, Andrew D. Medhurst, Derek N. Middlemiss, David J. Nash, Graham J. Riley, Carol Routledge, Geoff Stemp, Kevin M. Thewlis, Brenda Trail, Antonio K. K. Vong and Jim J. Hagan
Journal of Pharmacology and Experimental Therapeutics September 2000, 294 (3) 1154-1165;
Charlie Reavill
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen G. Taylor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martyn D. Wood
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tracey Ashmeade
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nigel E. Austin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kim Y. Avenell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Izzy Boyfield
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clive L. Branch
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jackie Cilia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martyn C. Coldwell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael S. Hadley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Jackie Hunter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Phil Jeffrey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frances Jewitt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher N. Johnson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Declan N. C. Jones
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew D. Medhurst
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Derek N. Middlemiss
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J. Nash
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Graham J. Riley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carol Routledge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geoff Stemp
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin M. Thewlis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brenda Trail
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio K. K. Vong
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jim J. Hagan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

SB-277011-A {trans-N-[4-[2-(6-cyano-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolininecarboxamide}, is a brain-penetrant, high-affinity, and selective dopamine D3 receptor antagonist. Radioligand-binding experiments in Chinese hamster ovary (CHO) cells transfected with human dopamine D3 or D2 long (hD3, hD2) receptors showed SB-277011-A to have high affinity for the hD3 receptor (pKi = 7.95) with 100-fold selectivity over the hD2 receptor and over 66 other receptors, enzymes, and ion channels. Similar radioligand-binding data for SB-277011-A were obtained from CHO cells transfected with rat dopamine D3 or D2. In the microphysiometer functional assay, SB-277011-A antagonized quinpirole-induced increases in acidification in CHO cells overexpressing the hD3 receptor (pKb = 8.3) and was 80-fold selective over hD2 receptors. Central nervous system penetration studies showed that SB-277011-A readily entered the brain. In in vivo microdialysis studies, SB-277011-A (2.8 mg/kg p.o.) reversed the quinelorane-induced reduction of dopamine efflux in the nucleus accumbens but not striatum, a regional selectivity consistent with the distribution of the dopamine D3 receptor in rat brain. SB-277011-A (2–42.3 mg/kg p.o.) did not affect spontaneous locomotion, or stimulant-induced hyperlocomotion. SB-277011-A (4.1–42.2 mg/kg p.o.) did not reverse prepulse inhibition deficits in apomorphine- or quinpirole-treated rats, but did significantly reverse the prepulse inhibition deficit in isolation-reared rats at a dose of 3 mg/kg p.o. SB-277011-A (2.5–78.8 mg/kg p.o.) was noncataleptogenic and did not raise plasma prolactin levels. Thus, dopamine D3 receptor blockade produces few of the behavioral effects characteristic of nonselective dopamine receptor antagonists. The effect of SB-277011-A on isolation-induced prepulse inhibition deficit suggests that blockade of dopamine D3 receptors may benefit the treatment of schizophrenia.

Footnotes

  • Send reprint requests to: Dr. Charlie Reavill, Neuroscience Research, SmithKline Beecham Pharmaceuticals, New Frontiers Science Park, Third Ave., Harlow, Essex CM19 5AW, UK. E-mail:Charlie_Reavill-1{at}SBPHRD.COM

  • Abbreviations:
    hD2
    human dopamine D2
    CHO
    Chinese hamster ovary
    rD2
    rat dopamine D2
    DMEM
    Dulbecco's modified Eagle's medium
    FBS
    fetal bovine serum
    RT-PCR
    reverse transcription-polymerase chain reaction
    PPI
    prepulse inhibition
    DMSO
    dimethyl sulfoxide
    CNS
    central nervous system
    LC/MS/MS
    liquid chromatography/mass spectrometry/mass spectrometry
    ISI
    interstimulus interval
    • Received February 18, 2000.
    • Accepted May 16, 2000.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 294 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 294, Issue 3
1 Sep 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacological Actions of a Novel, High-Affinity, and Selective Human Dopamine D3 Receptor Antagonist, SB-277011-A
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

Pharmacological Actions of a Novel, High-Affinity, and Selective Human Dopamine D3 Receptor Antagonist, SB-277011-A

Charlie Reavill, Stephen G. Taylor, Martyn D. Wood, Tracey Ashmeade, Nigel E. Austin, Kim Y. Avenell, Izzy Boyfield, Clive L. Branch, Jackie Cilia, Martyn C. Coldwell, Michael S. Hadley, A. Jackie Hunter, Phil Jeffrey, Frances Jewitt, Christopher N. Johnson, Declan N. C. Jones, Andrew D. Medhurst, Derek N. Middlemiss, David J. Nash, Graham J. Riley, Carol Routledge, Geoff Stemp, Kevin M. Thewlis, Brenda Trail, Antonio K. K. Vong and Jim J. Hagan
Journal of Pharmacology and Experimental Therapeutics September 1, 2000, 294 (3) 1154-1165;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleNEUROPHARMACOLOGY

Pharmacological Actions of a Novel, High-Affinity, and Selective Human Dopamine D3 Receptor Antagonist, SB-277011-A

Charlie Reavill, Stephen G. Taylor, Martyn D. Wood, Tracey Ashmeade, Nigel E. Austin, Kim Y. Avenell, Izzy Boyfield, Clive L. Branch, Jackie Cilia, Martyn C. Coldwell, Michael S. Hadley, A. Jackie Hunter, Phil Jeffrey, Frances Jewitt, Christopher N. Johnson, Declan N. C. Jones, Andrew D. Medhurst, Derek N. Middlemiss, David J. Nash, Graham J. Riley, Carol Routledge, Geoff Stemp, Kevin M. Thewlis, Brenda Trail, Antonio K. K. Vong and Jim J. Hagan
Journal of Pharmacology and Experimental Therapeutics September 1, 2000, 294 (3) 1154-1165;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CVN424, a novel GPR6 inverse agonist for Parkinson's disease
  • Methylone Brain Concentrations and Pharmacodynamic Effects
  • Oxysterols and Ethanol
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics